Altre lingue Pliant Therapeutics, Inc.

Azioni

PLRX

US7291391057

Tempo reale stimato Cboe BZX Altri mercati azionari 18:38:51 25/04/2024			Variaz. 5gg	Var. 1 gen.
11,5 ^USD	-3,36%		-5,74%	-36,55%

12/03	Pliant Therapeutics, Inc. annuncia un piano di sviluppo accelerato di Bexotegrast per il trattamento della fibrosi polmonare idiopatica	CI
05/03	PLIANT THERAPEUTICS, INC. : giudizio positivo da RBC Capital Markets	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pliant Therapeutics to Participate in Upcoming Investor Events	02/04
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference	27/03
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13/03
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03
Pliant Therapeutics : March 2024 Corporate Presentation	29/02
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	27/02
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	27/02
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26/02
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26/02
Pliant Therapeutics to Participate in Upcoming Investor Events	07/02
Pliant Therapeutics to Participate in Upcoming Investor Events	07/02
Pliant Therapeutics Reports Interim 'Positive' Safety, Efficacy Data for Potential Liver Disease Drug	05/02
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04/02
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04/02
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04/02
Pliant Therapeutics Insider Sold Shares Worth $443,173, According to a Recent SEC Filing	19/01
Top Premarket Decliners	11/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pliant Therapeutics, Inc.

Azioni

PLRX

US7291391057

Altre lingue

Filtri